Latest news with #BPOM
Barnama
26-05-2025
- Business
- Barnama
Top News Headlines In Cambodia, Indonesia, Laos, Myanmar, Singapore, & Thailand: May 26, 2025
National flag carrier, Air Cambodia, will complete the delivery of three ATR 72-600 aircraft this year. The first aircraft is scheduled to arrive at Phnom Penh International Airport today. The carrier operates domestic and international flights to China, Thailand and Vietnam. The government initiated a street food hygiene pilot project in Kampong Thom province to raise traders' awareness of food safety. As part of a national campaign, the project aims to promote public health and engage the informal economy. CHINA INK DEALS TO BOOST LOCAL CURRENCY USE AND EXPAND BILATERAL COOPERATION -- JAKARTA GLOBE Indonesia and China on Sunday agreed to promote the use of their respective national currencies in bilateral trade, marking a significant step toward reducing dependency on the US dollar. The agreement was formalised through a memorandum of understanding signed by Bank Indonesia and the People's Bank of China during Chinese Premier Li Qiang's official visit to Jakarta. HERBAL DRINK AS NATION'S HEALTH SYMBOL: BPOM -- ANTARA The National Food and Drug Agency (BPOM) emphasised that traditional herbal drink jamu is not merely a legacy of the past but a symbol of Indonesia's future health sector. The agency's Deputy for Traditional Medicines, Health Supplements, and Cosmetics Supervision stated that jamu represents local wisdom supported by strong scientific research and evidence. LAOS PAYMENT WITH VISA SUPPORT -- VIENTIANE TIMES The Agricultural Promotion Bank Co Ltd has partnered with VISA to promote cross-border digital payments. The launch of APB World-Remit with the support of VISA B2B Connect will help Lao businesses link up with international markets. OFFICIALS IRON OUT BILATERAL ISSUES -- VIENTIANE TIMES Traditional partners Laos and Thailand held talks on a wide range of issues from political and security cooperation to trade and investment. Foreign Ministry officials also discussed protecting Lao migrant workers' rights in neighbouring Thailand. MYANMAR KEY TO NATION'S STABILITY AND PROGRESS, SAYS LEADER -- THE GLOBAL NEW LIGHT OF MYANMAR State Administration Council Chairman Senior General Min Aung Hlaing said Myanmar is a union nation based on genuine multiparty democracy and a federal system. All parties have to unite to promote peace and stability in the country. EDIBLE FROG FARMING -- THE GLOBAL NEW LIGHT OF MYANMAR Rising demand and lucrative prices for edible frogs in the local market are encouraging more farmers to venture into the business. Called the 'Thai frog', it takes about three months to breed the frogs, which feed on bran and floating fish feed. SINGAPORE HAS REACHED 'CONSENSUS' ON TRADE, US TARIFFS AND POWER GRID AHEAD OF SUMMIT: ANWAR -- THE STRAITS TIMES Prime Minister Anwar Ibrahim is bullish that 'very constructive' outcomes will result from the Asean Summit and related meetings that Malaysia is hosting as regional leaders began meeting on May 23, citing progress on a regional power grid and the Myanmar civil war. TO SIGN IMPROVED CHINA, INTERNAL TRADE DEALS AS BLOC WEIGHS 'BOLDER' MOVES TO TACKLE US TARIFFS -- CNA Easier trade among members of the Association of Southeast Asian Nations (ASEAN) as well as with the regional bloc's top economic partner, China, is on the horizon as the grouping pushes ahead with 'bolder' moves to stave off the threat of steep US tariffs. THAILAND MINISTRY CRACKS DOWN ON ILLEGAL TOURS TO RESTORE TRUST -- THE NATION Natreeya Taweewong, Permanent Secretary of the Ministry of Tourism and Sports, has outlined the government's comprehensive plan to ensure the safety of tourists in Thailand, an issue that remains a top priority. SPENDING TIGHTENS -- BANGKOK POST Quiet tourist attractions with fewer guests and complaints from local merchants about stagnant purchasing power have become more pronounced, as the Thai economy braces for another slump in the second quarter, which is typically a low season for spending. -- BERNAMA BERNAMA provides up-to-date authentic and comprehensive news and information which are disseminated via BERNAMA Wires; BERNAMA TV on Astro 502, unifi TV 631 and MYTV 121 channels and BERNAMA Radio on FM93.9 (Klang Valley), FM107.5 (Johor Bahru), FM107.9 (Kota Kinabalu) and FM100.9 (Kuching) frequencies. Follow us on social media : Facebook : @bernamaofficial, @bernamatv, @bernamaradio Twitter : @ @BernamaTV, @bernamaradio Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial TikTok : @bernamaofficial
CNA
16-05-2025
- Health
- CNA
‘Not guinea pigs': Indonesian officials debunk rumours, defend safety of Bill Gates-backed TB vaccine trial
JAKARTA: The late-stage trial of a tuberculosis (TB) vaccine backed by Microsoft co-founder Bill Gates and involving over 2,000 Indonesians is safe and will bring benefits to the country, health officials said in the wake of conspiracy theories surrounding the vaccine. Controversy, including reported rumours and misinformation surrounding the M72/AS01E vaccine candidate, arose after Indonesian President Prabowo Subianto's remarks following his meeting with American philanthropist and Gates in Indonesia on May 7. Prabowo said Gates was 'developing a TB vaccine for the world' and that Indonesia would be 'one of the places to test' the vaccine. The president also praised Gates' contributions to the country, noting that his foundation had provided more than US$159 million in grants since 2009, mostly for health programmes. However, in the wake of Prabowo's comments, netizens expressed doubts about Indonesia being the 'testing ground' for the vaccine candidate. They questioned Gates' intention and why it was only being tested in 'poor countries'. Indonesia is the only country outside Africa to take part in the trial. VACCINE CANDIDATE IS SAFE: INDONESIAN AUTHORITIES Participating in the trial means Indonesians will be among the first to receive the TB vaccine, said Taruna Ikrar, head of the country's Food and Drug Supervisory Agency (BPOM), on Wednesday (May 14), as reported by news agency Antara. Vaccination is one of the most effective strategies to reduce TB prevalence in the country, he said. According to the World Health Organization (WHO), the estimated incidence of TB in Indonesia was 387 per 100,000 population in 2023. Indonesia sees over 1 million TB cases a year and was estimated to have the world's second-highest number of TB cases in 2023, after India. It accounted for 10 per cent of an estimated 10.8 million cases globally in 2023, according to the WHO's Global TB Report 2024. Indonesia recorded about 125,000 deaths from TB in 2023, according to Taruna. TB is an airborne infectious disease caused by a bacterium called Mycobacterium tuberculosis, and primarily affects the lungs. It can cause lung damage or death if untreated. The WHO has called M72 the most advanced TB vaccine candidate in development. Taruna said the vaccine to be trialled is safe, having undergone pre-clinical testing, toxicity studies and safety trials in line with international standards. 'Based on scientific evaluations, we have authorised the clinical trials of the TB vaccine in Indonesia,' he told Antara. 'There is no issue here. The TB vaccine will bring many benefits.' Health Minister Budi Gunadi Sadikin also assured the vaccine is safe. 'This is to educate the public, as well, that we are not guinea pigs,' he reportedly said on May 9. Rumours about the vaccine were 'intentionally spread so that people do not want to be vaccinated. In fact, the consequences can be very fatal, 100,000 people could die because of something like this,' Budi said on May 9. On Wednesday, Budi said the trial will help determine the vaccine's compatibility with Indonesia's population, as vaccine effectiveness can depend on genetic factors, reported news outlet Tempo. He said the trial involves scientists at Padjadjaran University and the University of Indonesia. If successful, Indonesia could eventually serve as a manufacturing site for the vaccine, he said. INDONESIA INVOLVED IN TB VACCINE TRIAL SINCE 2024 The M72 is developed by pharmaceutical firm GlaxoSmithKline in partnership with AERAS, a United States-based not-for-profit funded by the Bill and Melinda Gates Foundation and other organisations. Indonesia's involvement in the late-stage trial has been known since last year. New vaccines are urgently needed to tackle TB in Indonesia and globally, the WHO said in a news release in November 2024 when it convened the first national consultation on new TB vaccines together with Indonesia's Ministry of Health in Bali. The last TB vaccine was approved over 100 years ago. If M72's efficacy is confirmed in the late-stage trial, it could lead to the introduction of a new TB vaccine for adults and adolescents by 2030, said the WHO. The Phase 3 trial involves 20,000 participants from five countries. Besides the 2,095 people from Indonesia, the rest are from South Africa, Kenya, Malawi and Zambia. Africa had the second-highest number of TB cases in 2023 after Southeast Asia, according to the Global TB Report 2024. The earlier Phase 2b of the trial involved more than 3,500 people in South Africa, Zambia and Kenya, and results were 'cautiously encouraging', reported an article on May 13 by Gavi, the Vaccine Alliance, a global health partnership. 'In these adults, who were already thought to have been infected with the bacterium (TB bacteria can remain dormant for many years), the vaccine halved the risk of developing active TB over the next three years compared to a placebo, with an estimated efficacy of 50 per cent,' it reported. The rumours circulating in Indonesia about M72 is not the first time that conspiracy theories related to public health and Gates have arisen in Indonesia. In 2023, misinformation about Wolbachia mosquitoes stoked protests and delayed the rollout of a project in Bali that involved their release to fight dengue. The project involved the World Mosquito Programme, which is supported by the Bill and Melinda Gates Foundation.
Associated Press
30-04-2025
- Business
- Associated Press
Mobile-health Network Solutions Intends To Acquire Lifepack, Expanding into Indonesia's Growing Healthcare Market
Singapore, Singapore--(Newsfile Corp. - April 30, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ('MNDR' or 'the Company'), a leading MedTech innovator ranked among Asia-Pacific's high-growth companies, today announced an agreement intending to acquire Indopacific Health Technology Pte. Ltd. and its subsidiaries, known as Lifepack, a leading pharmacy and telehealth platform in Indonesia ('Acquisition'). Focus on Indonesia 'This acquisition is a significant step for MNDR as we expand into Indonesia, a high-growth market,' said Dr. Siaw Tung Yeng, PBM, Co-CEO and Senior Consultant Family Physician at MNDR. 'Lifepack's platform aligns with Indonesia's primary care needs and complements our telehealth expertise. Through this partnership, we're building a telehealth-pharmacy solution that meets BPOM (Indonesian National Agency of Drug and Food Control) standards, serving 280 million people across 17,000 islands. We look forward to completing due diligence and finalizing this deal.' The Acquisition, added Dr. Siaw, would allow MNDR to combine its global telehealth platform with Lifepack's local expertise to serve many of Indonesia's primary care needs, including improved teleconsultations, prescription fulfillment, and healthcare delivery to remote areas, while emphasizing immunization, nutrition, and chronic disease management. Dr. Siaw further commented, 'By combining Lifepack's strong presence and understanding of the Indonesian market with MNDR's innovative telehealth capabilities, we believe we can create a truly transformative O2O healthcare platform that addresses the unique needs of Indonesian's diverse population and significantly impact healthcare delivery across the archipelago.' Lifepack: Enhancing Indonesia's Primary Care Lifepack improves healthcare access in Indonesia, the fourth most populous nation globally, with over 280 million people and a growing demand for affordable medical services. Lifepack's hybrid model delivers BPOM-licensed prescription drugs, over-the-counter medications, supplements, and medical equipment through online and offline channels, serving millions nationwide. Lifepack also offers consultations with physicians and pharmacists, available via its mobile app and website, through WhatsApp and social media, and at physical locations, supported by an expanding warehouse network, to address chronic disease management and preventive care. Compliant with Indonesia's BPOM regulations, Lifepack's scalable platform and steady user growth position it to lead the Indonesian digital pharmacy market. By supporting primary care needs, especially in remote and rural areas, Lifepack is a key part of MNDR's regional strategy. MNDR would acquire Lifepack for up to US$7.2 million, contingent upon Lifepack achieving its revenue target for 2025. The consideration for the Acquisition is expected to be satisfied through the issuance of up to 875,000 new MNDR Class A Ordinary Shares, valued at an issue price of US$8 per share, alongside a non-refundable cash payment of US$0.2 million. The US$8 per share issue price represents a substantial premium to MNDR's current share price of approximately US$1.42 as of April 29, 2025, underscoring the perceived value and future potential of the combined entity. Subject to due diligence and execution of definitive agreements, the deal is expected to strengthen MNDR's presence in Southeast Asia through partnerships with Indonesian healthcare stakeholders. 'We look forward to completing the current due diligence process and proceeding to the completion of this Acquisition,' said Dr. Siaw. About Mobile-health Network Solutions Ranked #41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies, we are the first telehealth provider from the Asia-Pacific region to be listed in the US. Through our platform, we offer personalized and reliable medical attention to users worldwide. Our platform allows our community of healthcare providers to have broader reach to users through virtual clinics without any start-up costs and the ability to connect to a global network of peer-to-peer support groups and partners. Our range of seamless and hassle-free telehealth solutions includes teleconsultation services, prescription fulfillment and other personalized services such as weight management programs and gender-specific care. For more information, please visit our website. About Lifepack Lifepack is a pharmacy service that offers a variety of over-the-counter medications, prescription drugs, supplements, and medical equipment at affordable prices. The company provides original products, licensed by BPOM, and delivers across Indonesia. Lifepack services are available both online and offline, accessible through its website, social media channels, WhatsApp, and its mobile app. FORWARD-LOOKING STATEMENTS Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to execute our strategies, manage growth and maintain our corporate culture; the Company's future business development, financial conditions and results of operations; expectations regarding demand for and market acceptance of our products and services; changes in technology; economic conditions; the growth of the telehealth solutions industry in Singapore and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Singapore and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Mobile-health Network Solutions specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise, except as required by law. For media inquiries, please contact: Mobile-health Network Solutions 2 Venture Drive, #07-06/07 Vision Exchange Singapore 608526 (+65) 6222 5223 Email: [email protected] Investor Relations Inquiries: Skyline Corporate Communications Group, LLC Scott Powell, President 1177 Avenue of the Americas, 5 th Floor New York, New York 10036 Office: (646) 893-5835 Email: [email protected] To view the source version of this press release, please visit
Yahoo
30-04-2025
- Business
- Yahoo
Mobile-health Network Solutions Intends To Acquire Lifepack, Expanding into Indonesia's Growing Healthcare Market
Singapore, Singapore--(Newsfile Corp. - April 30, 2025) - Mobile-health Network Solutions (NASDAQ: MNDR) ("MNDR" or "the Company"), a leading MedTech innovator ranked among Asia-Pacific's high-growth companies, today announced an agreement intending to acquire Indopacific Health Technology Pte. Ltd. and its subsidiaries, known as Lifepack, a leading pharmacy and telehealth platform in Indonesia ("Acquisition"). Focus on Indonesia "This acquisition is a significant step for MNDR as we expand into Indonesia, a high-growth market," said Dr. Siaw Tung Yeng, PBM, Co-CEO and Senior Consultant Family Physician at MNDR. "Lifepack's platform aligns with Indonesia's primary care needs and complements our telehealth expertise. Through this partnership, we're building a telehealth-pharmacy solution that meets BPOM (Indonesian National Agency of Drug and Food Control) standards, serving 280 million people across 17,000 islands. We look forward to completing due diligence and finalizing this deal." The Acquisition, added Dr. Siaw, would allow MNDR to combine its global telehealth platform with Lifepack's local expertise to serve many of Indonesia's primary care needs, including improved teleconsultations, prescription fulfillment, and healthcare delivery to remote areas, while emphasizing immunization, nutrition, and chronic disease management. Dr. Siaw further commented, "By combining Lifepack's strong presence and understanding of the Indonesian market with MNDR's innovative telehealth capabilities, we believe we can create a truly transformative O2O healthcare platform that addresses the unique needs of Indonesian's diverse population and significantly impact healthcare delivery across the archipelago." Lifepack: Enhancing Indonesia's Primary Care Lifepack improves healthcare access in Indonesia, the fourth most populous nation globally, with over 280 million people and a growing demand for affordable medical services. Lifepack's hybrid model delivers BPOM-licensed prescription drugs, over-the-counter medications, supplements, and medical equipment through online and offline channels, serving millions nationwide. Lifepack also offers consultations with physicians and pharmacists, available via its mobile app and website, through WhatsApp and social media, and at physical locations, supported by an expanding warehouse network, to address chronic disease management and preventive care. Compliant with Indonesia's BPOM regulations, Lifepack's scalable platform and steady user growth position it to lead the Indonesian digital pharmacy market. By supporting primary care needs, especially in remote and rural areas, Lifepack is a key part of MNDR's regional strategy. MNDR would acquire Lifepack for up to US$7.2 million, contingent upon Lifepack achieving its revenue target for 2025. The consideration for the Acquisition is expected to be satisfied through the issuance of up to 875,000 new MNDR Class A Ordinary Shares, valued at an issue price of US$8 per share, alongside a non-refundable cash payment of US$0.2 million. The US$8 per share issue price represents a substantial premium to MNDR's current share price of approximately US$1.42 as of April 29, 2025, underscoring the perceived value and future potential of the combined entity. Subject to due diligence and execution of definitive agreements, the deal is expected to strengthen MNDR's presence in Southeast Asia through partnerships with Indonesian healthcare stakeholders. "We look forward to completing the current due diligence process and proceeding to the completion of this Acquisition," said Dr. Siaw. About Mobile-health Network Solutions Ranked #41 in the Financial Times 2024 listing of 500 High-growth Asia-Pacific Companies, we are the first telehealth provider from the Asia-Pacific region to be listed in the US. Through our platform, we offer personalized and reliable medical attention to users worldwide. Our platform allows our community of healthcare providers to have broader reach to users through virtual clinics without any start-up costs and the ability to connect to a global network of peer-to-peer support groups and partners. Our range of seamless and hassle-free telehealth solutions includes teleconsultation services, prescription fulfillment and other personalized services such as weight management programs and gender-specific care. For more information, please visit our website. About LifepackLifepack is a pharmacy service that offers a variety of over-the-counter medications, prescription drugs, supplements, and medical equipment at affordable prices. The company provides original products, licensed by BPOM, and delivers across Indonesia. Lifepack services are available both online and offline, accessible through its website, social media channels, WhatsApp, and its mobile app. FORWARD-LOOKING STATEMENTS Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's ability to execute our strategies, manage growth and maintain our corporate culture; the Company's future business development, financial conditions and results of operations; expectations regarding demand for and market acceptance of our products and services; changes in technology; economic conditions; the growth of the telehealth solutions industry in Singapore and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in Singapore and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Mobile-health Network Solutions specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise, except as required by law. For media inquiries, please contact:Mobile-health Network Solutions2 Venture Drive, #07-06/07 Vision Exchange Singapore 608526(+65) 6222 5223Email: investors@ Investor Relations Inquiries:Skyline Corporate Communications Group, LLCScott Powell, President1177 Avenue of the Americas, 5th FloorNew York, New York 10036Office: (646) 893-5835Email: info@ To view the source version of this press release, please visit Sign in to access your portfolio
Rakyat Post
23-04-2025
- Health
- Rakyat Post
Porcine DNA In Jelly, Marshmallow Products Tested By Indonesian Halal Body, Jakim Conducting Local Checks
Subscribe to our FREE It was all over the news yesterday that the Malaysian Islamic Development Department (Jakim) instructed importers to recall nine food products from the market. Jakim's statement was based on an announcement made by the Indonesian authority on halal, Badan Penyelenggara Jaminan Produk Halal (BPJPH). Let's dive into the The Indonesian body had conducted market sampling together with the country's food and drugs authority, Badan Pengawas Obat dan Makanan (BPOM). They discovered porcine DNA in 11 batches of 9 products. Of the 9, 7 are holders of Indonesia's halal certificate, while 2 have no halal certification. Despite issuing a statement for Malaysians, Jakim made no mention of the names of the products. So we go back to the Indonesian statement. 7 products with halal certification issued by BPJPH now being recalled from the Indonesian market: 1 – Corniche Fluffy Jelly, origin country: the Philippines. Batch No: 09052212 S2 Batch No: 08192251 S1 2 – Corniche Apple Teddy Marshmallow, origin country: the Philippines. Batch No: 02122212 B1 3 – ChompChomp Car Mallow, origin country: China Batch No: 151223 B 4 – ChompChomp Flower Mallow, origin country: China Batch No: 101023 B 5 – ChompChomp Mini Marshmallow, origin country: China Batch No: N0231123 A 6 – Hakiki Gelatin, produced by: PT Hakiki Donarta, Indonesia Batch No: HG1252201.230801 Batch No: HF2502403.240801 7 – Larbee TYL Vanilla Marshmallow Filling, origin country: China Batch No: CVT 2024 – 13 A Two products of which its market samples were found to contain porcine DNA but are not halal certificate holders. However, they are holders of the BPOM approval to distribute: 8 – AAA Marshmallow Rasa Jeruk (pickle-flavoured marshmallows??), origin country: China Batch No: 268 9 – Sweetime Chocolate-Flavoured Marshmallow, origin country: China Batch No: MRS24-101223 Coming back to Malaysia, Jakim informed that they are conducting checks with state Islamic councils and departments to see if these products are available in the Malaysian market. KENYATAAN MEDIA JABATAN KEMAJUAN ISLAM MALAYSIA (JAKIM) BERKENAAN PENGUMUMAN PENARIKAN BALIK PRODUK MAKANAN YANG DIPERSIJILKAN HALAL DI INDONESIA — JAKIM (@MyJAKIM) Jakim has also instructed the importers concerned to recall these products immediately from the Malaysian market. Share your thoughts with us via TRP's . Get more stories like this to your inbox by signing up for our newsletter.
